Peter Valk, PhD, Erasmus University Medical Center, Rotterdam, Netherlands, shares some insights into a study which aimed to investigate the clinical and molecular differences between TP53-mutated high-risk (HR) myelodysplastic syndromes (MDS) and TP53-mutated acute myeloid leukemia (AML). Dr Valk explains that there were no differences observed between the two diseases, and that patients with both diseases have poor outcomes. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.